Roche and SeqWright Collaborate to Help Elucidate the Underlying Genetic Causes of Heart Disease
News Jun 09, 2009
Utilizing next generation sequencing and the latest advancements in sequence capture, SeqWright has announced a collaboration with Roche Applied Science and the University of Miami Miller School of Medicine.
The research focuses on a major study to help identify possible genetic variants associated with dilated cardiomyopathy, a disease of heart muscle. In this collaboration SeqWright used NimbleGen Sequence Capture Human Exome Arrays to enrich over 180,000 exons from DNA samples from individuals affected with dilated cardiomyopathy.
Using the Genome Sequencer FLX, a technology of 454 Life Sciences, SeqWright is sequencing the enriched exons to detect genetic variants within these samples, including single nucleotide polymorphisms (SNP’s) and insertions and deletions. The complete solution from Roche allows targeted re-sequencing of all of the coding exons, called the human exome, representing the portion of the human genome that is transcribed and translated into the myriad of proteins that function within all cells in the human body.
“Sequencing the entire coding portion of the human genome has not been feasible until recent advancements in next generation genomic tools. By being able to efficiently characterize the entire human exome, researchers can accelerate their research by taking the ‘candidate gene’ approach to a completely new level,” stated Fei Lu, M.D., CEO of SeqWright. “It’s truly amazing to see just how fast research has transformed with these tools and I’m proud to see that SeqWright has stayed ahead of the community as we adopt these technologies almost as fast as they are developed.”
“Dilated cardiomyopathy is a leading cause of heart failure that carries a high mortality rate,” stated Nadine Norton, PhD, a Research Assistant Professor from the University of Miami Miller School of Medicine.
“We know that familial dilated cardiomyopathy (FDC) can be explained by mutations in more than 20 autosomal and two X-linked genes, yet mutations in these genes account for only one-third of the cause. By using an experimental strategy that employs the sequencing of all coding regions within the human genome, we hope to identify other mutations in other genes that cause this terrible disease.”
This work is part of an ongoing 15 year study of familial dilated cardiomyopathy brought to the Miller School of Medicine in 2007 by Ray Hershberger, MD, professor of medicine and associate chief of the Cardiovascular Division.
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE